You are here

Article info

Article menu
PDF
Commentary
Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression

Authors

  • Fernando Magdaleno Department of Internal Medicine I, University of Bonn, Bonn, Germany Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Jonel Trebicka Department of Internal Medicine I, University of Bonn, Bonn, Germany Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense, Denmark European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Jonel Trebicka, European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, 11, 7th floor, Barcelona 08021, Spain; jonel.trebicka{at}efclif.com
View Full Text

Citation

Magdaleno F, Trebicka J
Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression
Gut 2017;66:1540-1541.

Publication history

  • Received 31 January 2017
  • Revised 8 February 2017
  • Accepted 9 February 2017
  • Published in print 1 September 2017.
  • Published online 9 August 2017.
  • Published first 28 February 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/